Clinical trial
Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults…
NCT00247572 · New River Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00247572 |
|---|---|
| Title | Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories |
| Official title | A Double-Blind Placebo- and Active-Controlled, Single-Dose Crossover PD and PK Study to Evaluate the Safety, Tolerability and Abuse Liability of IV Administered NRP104 25 mg and 50 mg in Adult Volunteers With Histories of Stimulant Abuse |
| Lead sponsor | New River Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders |
| Intervention type | Drug |
| Interventions | NRP104 |
| Enrollment | 12 |
| Start date | Sep 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Nov 2, 2005 |
| Last update posted | Nov 5, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: